|Day's Range||1.27 - 1.45|
|52 Week Range||1.27 - 8.00|
|PE Ratio (TTM)||-2.75|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In early December 2016, Critical Outcome Technologies (COT.V) (COTQF) appointed Alison Silva as the Company’s new Chief Executive Officer (CEO) effective January 1, 2017. Ms. Silva served before the appointment on the Board of Directors and as President. Alison has worked with COT.V in various roles since 2013, during which time she has been integral in shaping the Company’s orphan drug development strategy.
The higher R&D expenses for the quarter were primarily due to the addition of clinical trial expenses, whereas there was no comparable expense in the same quarter of FYE 2015. The addition of clinical trial expenses was partially offset by a reduction in synthesis and miscellaneous R&D expenses with much of this reduction related to consulting fees incurred in writing and conducting additional tests in support of the IND submission to the FDA which occurred late in the fourth quarter of FYE 2015. The Company (COT.V) reported a quarterly net loss of $2.4 million ($0.02 per share) for fiscal 4Q16, compared to a net loss of $0.95 million ($0.01 per share) for the fourth quarter of the previous year.
By Grant Zeng, CFA TSX:COT.V On March 17 , 2016, COTI (TSX:COT.V) announced that it realized gross proceeds of $1,447,125 upon the exercise of 4,823,750 common share purchase warrants that would otherwise ...